# Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy

> **NCT04207775** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 300 (actual)

## Conditions studied

- Locally Advanced or Metastatic NSCLC

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04207775
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-30
- **Primary completion:** 2023-09-01
- **Final completion:** 2023-09-01
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2024-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04207775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04207775, "Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04207775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*